Know the risks

Meningococcal disease can be spread by everyday teenage activities

If you’re a parent, your number one concern is protecting your child. And while you may have heard that some groups of people are at higher risk for meningococcal disease, you may not be aware that adolescents are near the top of those groups at a greater risk of catching this potentially fatal illness.1

Take a moment to answer these questions to find out if your child is at risk.

Does your teen or preteen participate in any of the following behaviors?

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
Submit

You’ve indicated that your child:

  1. Shares drinking glasses, eating utensils, food
  2. Lives in a dormitory
  3. Shares makeup
  4. Kisses a boyfriend or girlfriend
  5. Goes to overnight camp
  6. Shares water bottles
  7. Smokes or inhales secondhand smoke

The activities indicated may put your child at increased risk for meningococcal meningitis.

Teens and preteens in general are at greater risk than most people in the United States. That’s why the Centers for Disease Control and Prevention (CDC) recommends vaccination for children 11 through 18 years of age.2

You have not indicated any specific behaviors that would put your child at increased risk

However, adolescents in general are at greater risk for meningococcal disease.

That’s why the Centers for Disease Control and Prevention (CDC) recommends vaccination for children 11 through 18 years of age.2

Indication

Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 11 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.

Important Safety Information

You should not receive Menveo if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as Menveo.

Side effects to Menveo include pain at the injection site, headache, muscle pain, fatigue, nausea, and fainting. Sometimes fainting is accompanied by falling with injury. Other side effects may occur.

Following vaccination with a US-licensed meningococcal conjugate vaccine, an evaluation of postmarketing adverse events suggested a potential for increased risk of Guillain-Barré Syndrome (GBS). There is not enough information to evaluate if a risk of GBS exists following administration of Menveo.

Tell your doctor if you are pregnant or planning to get pregnant.

Vaccination with Menveo may not protect all individuals.

For more information about Menveo, talk to your health-care professional.

Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.

References

  1. Meningitis: People most at risk. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/high-risk/index.html. Accessed February 18, 2010.
  2. Meningitis: Meningococcal vaccination. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/vaccine-info.html. Accessed March 3, 2010.
  3. World Health Organization. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec. 2002;77;331–339. http://www.who.int/docstore/wer/pdf/2002/wer7740.pdf. Accessed March 3, 2010.

Menveo.com Exit Notice

You are now leaving the Menveo.com site and moving to an external website independently operated and not managed by Novartis Vaccines and Diagnostics Inc. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or, click OK to continue.

OKCancel